The Dominant Component and Clinicopathological Characteristics of Combined Hepatocellular-cholangiocarcinoma After Radical Resection

被引:1
|
作者
Matsubara, Keiso [1 ]
Kobayashi, Tsuyoshi [1 ]
Tadokoro, Takeshi [1 ]
Namba, Yosuke [1 ]
Fukuhara, Sotaro [1 ]
Oshita, Ko [1 ]
Honmyo, Naruhiko [1 ]
Kuroda, Shintaro [1 ]
Arihiro, Koji [2 ]
Ohdan, Hideki [1 ]
机构
[1] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol & Transplant Surg, 1-2-3 Kasumi,Minami Ku, Hiroshima 7348551, Japan
[2] Hiroshima Univ Hosp, Dept Anat Pathol, Hiroshima, Japan
关键词
Hepatocellular carcinoma; cholangiocarcinoma; classification; hepatectomy; CARCINOMA; FEATURES;
D O I
10.21873/anticanres.17284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver carcinoma, characterized by the unequivocal presence of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). However, its clinicopathological characteristics have not yet been thoroughly elucidated. In particular, cholangiolocellular carcinoma (CLC) was classified as a subtype of cHCC-CCA according to the 2010 World Health Organization (WHO) classification. However, according to the 2019 WHO classification, tumors displaying histological features consistent with CLC but lacking evidence of hepatocellular differentiation should be regarded as a distinct subtype of iCCA. Nevertheless, there may be notable differences in prognosis between CLC and iCCA, indicating the necessity for refining the classification when devising clinical treatment strategies. This study aimed to determine the clinicopathological features and prognostic factors of cHCC-CCAs following radical resection. Patients and Methods: Between January 2010 and September 2020, based on the 2010 WHO classification, we retrospectively studied the clinicopathological features and prognoses of patients with cHCC-CCAs in relation to the pathological dominant classification. The patients were classified according to the pathological dominant components of cHCC-CCA as HCC-dominant (HCC-D), iCCA-dominant (iCCA-D), or CLC-dominant (CLC-D). Results: Data of 55 patients who underwent primary radical hepatectomy for cHCC-CCA were analyzed. The prevalences of each dominant classification were HCC-D, 21 (38.2%); iCCA-D, 11 (20.0%); and CLC-D, 23 (41.8%). Multivariate analysis showed that dominant classification was an independent risk factor for recurrence and cancer-specific survival (CSS). Conclusion: The dominant classification of cHCC-CCA has the potential to predict recurrence and CSS.
引用
收藏
页码:4551 / 4559
页数:9
相关论文
共 50 条
  • [41] The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value
    Sheng, Ruofan
    Yang, Chun
    Zhang, Yunfei
    Wang, Heqing
    Zheng, Beixuan
    Han, Jing
    Sun, Wei
    Zeng, Mengsu
    RADIOLOGIA MEDICA, 2023, 128 (09): : 1047 - 1060
  • [42] COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA: AN INDICATION FOR LIVER TRANSPLANTATION?
    Schaefer, I. -M.
    Reinecke, J. A.
    Goralczyk, A.
    Schultze, F. C.
    Amanzada, A.
    Schweyer, S.
    Lorf, T.
    Obed, A.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 39 - 39
  • [43] Carcinoma of ectopic liver tissue shares characteristics with combined hepatocellular-cholangiocarcinoma
    Geng, Shi-Kai
    Zhou, Jian-Hong
    Liu, You-Jun
    Xu, Li-Ping
    Wang, Nong-Rong
    Sun, Jian
    Chen, Nan-Ping
    Yu, Xue-Feng
    Deng, Jun
    Yin, Sheng-Jiang
    Wang, Meng-Meng
    Su, Yue
    Lu, Qi
    Qu, Qiang-Guan
    Yi, Fan
    Mei, Jin-Hong
    Feng, Qiong
    Gong, Zhi-Qiang
    Yang, Hong-Wu
    Deng, Huan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (11): : 12142 - 12153
  • [44] The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value
    Ruofan Sheng
    Chun Yang
    Yunfei Zhang
    Heqing Wang
    Beixuan Zheng
    Jing Han
    Wei Sun
    Mengsu Zeng
    La radiologia medica, 2023, 128 : 1047 - 1060
  • [45] EXPRESSION OF ABH AND LEWIS BLOOD-GROUP ANTIGENS IN COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA - POSSIBLE EVIDENCE FOR THE HEPATOCELLULAR ORIGIN OF COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA
    OKADA, Y
    JINNO, K
    MORIWAKI, S
    MORICHIKA, S
    TORIGOE, SI
    ARIMA, T
    NAGASHIMA, H
    KOPROWSKI, H
    CANCER, 1987, 60 (03) : 345 - 352
  • [46] Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki, M.
    Sato, Y.
    Nakanuma, Y.
    HISTOPATHOLOGY, 2022, 80 (05) : 859 - 868
  • [47] Imaging features of combined hepatocellular-cholangiocarcinoma on contrast-enhanced ultrasound: correlation with clinicopathological findings
    Ye, J.
    Xie, X.
    Lin, Y.
    Liu, B.
    Wang, W.
    Huang, X.
    Huang, G.
    CLINICAL RADIOLOGY, 2018, 73 (03) : 237 - 243
  • [48] A HISTOCHEMICAL-STUDY ON COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA
    UEKUSA, T
    MASTUMOTO, T
    ABE, H
    FUKUDA, Y
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 1985, 18 (06) : 673 - 673
  • [49] Epigenetic regulation of combined hepatocellular-cholangiocarcinoma subtypes
    Schachtschneider, Kyle M.
    Lokken, Ryan Peter
    Huang, Yu-Hui
    Guzman, Grace
    Schook, Lawrence B.
    Gaba, Ron C.
    CANCER RESEARCH, 2019, 79 (13)
  • [50] COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA - A HISTOLOGIC AND IMMMUNOHISTOCHEMICAL STUDY
    GOODMAN, ZD
    ISHAK, KG
    LANGLOSS, JM
    SESTERHENN, IA
    RABIN, L
    CANCER, 1985, 55 (01) : 124 - 135